The U.S. Court of International Trade issued a ruling on September 2, 2026, that affects Zoetis Services LLC, a pharmaceutical company. The court decided that the company's imported feed-grade chlortetracycline concentrate should be classified as an antibiotic, rather than as a preparation for animal feed. This ruling is significant because it impacts how similar products are classified and taxed in the future.
Zoetis Services LLC, based in the United States, imported the chlortetracycline concentrate from Jinhe Biotechnology Co., Ltd. in China. The U.S. Customs and Border Protection initially classified the product under heading 2309 of the Harmonized Tariff Schedule of the United States (HTSUS), which pertains to preparations used in animal feeding. However, Zoetis argued that the concentrate, which contains chlortetracycline as its only active ingredient, should be classified under heading 2941 as an antibiotic. The dispute arose after Zoetis protested the classification and paid the assessed duties, leading to the court case.
The court's decision came after both parties filed cross-motions for summary judgment. Zoetis sought a ruling that the imported product was an antibiotic, while the government maintained that it should remain classified as a feed preparation. The judge, Joseph A. Laroski, Jr., presided over the case and ultimately sided with Zoetis.
The court ruled that the imported chlortetracycline concentrate is properly classified as an antibiotic under subheading 2941.30.00, stating, "the imported merchandise is not classifiable under heading 2309 as a 'preparation[] of a kind used in animal feed.'" This decision highlights the court's interpretation of the product's composition and intended use, emphasizing that the concentrate's primary function is as an antibiotic rather than as a feed ingredient.
In its ruling, the court noted that the chlortetracycline concentrate is a broad-spectrum antibiotic and is not intended to be a significant source of nutrition for animals. Instead, it is used in the production of medicated articles that require veterinary oversight for use in animal feed. The court found that the non-antibiotic substances present in the concentrate are permissible impurities resulting from the manufacturing process and do not alter its classification as an antibiotic.
This ruling has implications for the pharmaceutical and agricultural industries, particularly for companies involved in the importation of veterinary pharmaceuticals. By classifying the chlortetracycline concentrate as an antibiotic, the court sets a precedent for how similar products may be classified in the future, potentially affecting import duties and regulatory compliance.
Looking ahead, it remains to be seen whether the U.S. government will appeal this decision. The court's ruling could influence ongoing and future cases involving the classification of veterinary pharmaceuticals under U.S. customs law. The outcome may also prompt other companies to reassess their product classifications and compliance strategies in light of this precedent.